Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
| Title | Publication Date | Price | Relevance |
|---|---|---|---|
| Currently Druggable in Breast Cancer A Drug Target Competitive Analysis |
Aug 2008 | £1,620 | 100% |
| Currently Druggable in Melanoma A Drug Target Competitive Analysis |
Oct 2008 | £1,620 | 99% |
| Currently Druggable in Prostate Cancer A Drug Target Competitive Analysis |
Sep 2008 | £1,620 | 99% |
| Currently Druggable in Colorectal Cancer A Drug Target Competitive Analysis |
Dec 2008 | £1,620 | 98% |
| Commercializing Cancer Vaccines A Decision Support Tool for Optimizing the Pipeline |
Oct 2010 | £1,620 | 95% |
| Leukemia A Competitive Analysis to New Products, Portfolio Planning, Licensing & Acquisition Through Pipeline Benchmarking |
Apr 2009 | £1,620 | 94% |
| Biomarker Technology Platforms for Cancer Diagnoses and Therapies | Sep 2011 | £2,150 | 94% |
| Cancer Biomarkers Adoption Is Driving Growth |
Jul 2008 | £2,370 | 93% |
| A Decision Support Tool for Optimizing The Lymphoma Pipeline From Research and Development to Market |
May 2011 | £1,620 | 93% |
| RNA therapy: the next big thing after monoclonal antibodies? | Oct 2008 | £4,805 | 92% |
| A Decision Support Tool for Optimizing the Prostate Cancer Pipeline From Research and Development to Market |
May 2010 | £1,620 | 92% |
| Orphan Drugs Strategic Approaches for the Industry | Jan 2012 | £695 | 92% |
| Portfolio Analytics in the Pancreatic Cancer Pipeline and Portfolio Planning High Unmet Medical Need but Where to Target? |
Mar 2010 | £1,620 | 92% |
| Portfolio Analytics and Planning in the Breast Cancer Pipeline Change is Around the Corner in a Highly Competitive Market Place |
Apr 2010 | £1,620 | 91% |
| Nanobiotechnology (2 parts) Applications, Markets and Companies |
Jan 2012 | £3,240 | 90% |
| Diabetes Therapies & Diagnostics Global Markets |
Jun 2010 | £3,065 | 90% |
| Alzheimer's disease Technologies, Markets and Companies |
Jan 2012 | £2,265 | 89% |
| Competitive Outlook on Lung Cancer Drug Development The Missing Handbook to New Product Planning and Portfolio Planning |
Aug 2009 | £2,035 | 89% |
| Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market | Jul 2011 | £1,620 | 88% |
| Biomarkers (2 parts) Technologies, Markets and Companies |
Jan 2012 | £3,240 | 88% |
| Molecular Diagnostics in Cancer Testing | Jul 2011 | £2,150 | 88% |
| Lymphoma Drug Development Strategies at Work Define Your Competition |
Jun 2009 | £1,620 | 88% |
| Commercializing Apoptotic Drugs in Cancer The Faster Route to Consider Your Options and Position of Others |
Dec 2011 | £2,035 | 86% |
| Protein Kinase Therapeutics in Oncology Where to Commercialize? |
Oct 2009 | £2,035 | 86% |
| Commercializing Cancer Drugs Affecting Angiogenesis: A Decision Support Tool for Optimizing the Pipeline | Sep 2010 | £2,035 | 85% |
| Biotechnologies for Medical Applications Global Markets |
May 2010 | £3,065 | 82% |
| China Bio-Pharma Profiles 2005 | Nov 2005 | £975 | 82% |
| Regenerative Medicines: Bone and Joint Applications | Oct 2009 | £3,065 | 81% |
| Molecular Diagnostics Markets | Jul 2011 | £2,150 | 80% |
| Analyzing Edible Vaccines | May 2010 | £950 | 79% |
